Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/18124
Full metadata record
DC FieldValueLanguage
dc.contributor.authorHafeez, Umbreen-
dc.contributor.authorGan, Hui K-
dc.contributor.authorScott, Andrew M-
dc.date2018-06-05-
dc.date.accessioned2018-08-07T06:30:04Z-
dc.date.available2018-08-07T06:30:04Z-
dc.date.issued2018-06-05-
dc.identifier.citationCurrent opinion in pharmacology 2018; 41: 114-121-
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/18124-
dc.description.abstractSince Nobel laureate Paul Ehrlich proposed the concept of magic bullet in 1906, Köhler and Milstein discovered Hybridoma technology in 1975, and Greg Winter pioneered the technique to humanize monoclonal antibodies in 1988, monoclonal antibodies have been successfully developed to treat medical illnesses. Monoclonal antibodies are effective treatments for inhibition of alloimmune reactivity, haematological malignancies, solid organ malignancies, viral illnesses and are also used as antiplatelet therapy. Their successful use in cancer and autoimmune diseases in humans have made them one of the fastest growing classes of new drugs approved for these indications in last few decades. This review focuses on the role of monoclonal antibodies as an immunomodulatory therapy against cancer and autoimmune diseases, the strategies used to enhance efficacy, and how resistance mechanisms are being addressed to improve therapeutic outcomes for patients.-
dc.language.isoeng-
dc.titleMonoclonal antibodies as immunomodulatory therapy against cancer and autoimmune diseases.-
dc.typeJournal Article-
dc.identifier.journaltitleCurrent opinion in pharmacology-
dc.identifier.affiliationOlivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia-
dc.identifier.affiliationSchool of Cancer Medicine, LaTrobe University, Melbourne, Australia-
dc.identifier.affiliationDepartment of Medical Oncology, Austin Health, Heidelberg, Victoria, Australia-
dc.identifier.affiliationDepartment of Molecular Imaging and Therapy, Austin Health, Heidelberg, Victoria, Australia-
dc.identifier.doi10.1016/j.coph.2018.05.010-
dc.identifier.orcid0000-0002-6656-295X-
dc.identifier.pubmedid29883853-
dc.type.austinJournal Article-
dc.type.austinReview-
local.name.researcherGan, Hui K
item.languageiso639-1en-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.openairetypeJournal Article-
crisitem.author.deptMedical Oncology-
crisitem.author.deptMedical Oncology-
crisitem.author.deptOlivia Newton-John Cancer Wellness and Research Centre-
crisitem.author.deptMolecular Imaging and Therapy-
crisitem.author.deptOlivia Newton-John Cancer Research Institute-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

52
checked on Dec 22, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.